Empagliflozin's role in cardiometabolic disease treatment: an Egyptian expert's view.
- DOI
- 10.1186/s13098-026-02312-y
- Published
- 2026 Oct 30
- Container
- Diabetology & metabolic syndrome
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13098-026-02312-y,
title = {Empagliflozin's role in cardiometabolic disease treatment: an Egyptian expert's view.},
author = {Assaad-Khalil SH and Elmessallamy F and Elhadidy KE and El Hefnawy MH and Halawa MR and Zeitoun M and Hussein S and Elebrashy I},
year = {2026},
journal = {Diabetology \& metabolic syndrome},
doi = {10.1186/s13098-026-02312-y},
url = {https://doi.org/10.1186/s13098-026-02312-y}
}RIS
TY - JOUR TI - Empagliflozin's role in cardiometabolic disease treatment: an Egyptian expert's view. AU - Assaad-Khalil SH AU - Elmessallamy F AU - Elhadidy KE AU - El Hefnawy MH AU - Halawa MR AU - Zeitoun M AU - Hussein S AU - Elebrashy I PY - 2026 JO - Diabetology & metabolic syndrome DO - 10.1186/s13098-026-02312-y UR - https://doi.org/10.1186/s13098-026-02312-y ER -
APA
SH, A., F, E., KE, E., MH, E. H., MR, H., M, Z., S, H., & I, E. (2026). Empagliflozin's role in cardiometabolic disease treatment: an Egyptian expert's view.. Diabetology & metabolic syndrome. https://doi.org/10.1186/s13098-026-02312-y
Source records
- pubmed · retrieved 2026-11-10T15:11:30.826Z